Page title
Medication-Assisted Treatment – Prescription Drug and Opioid Addiction

Main page content

Short Title: MAT- PDOA
Initial Announcement Back to the Grants Dashboard

Notice of Funding Opportunity (NOFO)

NOFO Number: TI-22-013

Posted on Grants.gov: Monday, February 28, 2022

Application Due Date: Friday, April 29, 2022

Catalog of Federal Domestic Assistance (CFDA) Number: 93.243

Intergovernmental Review (E.O. 12372): Applicants must comply with E.O. 12372 if their state(s) participates. Review process recommendations from the State Single Point of Contact (SPOC) are due no later than 60 days after application deadline.

Public Health System Impact Statement (PHSIS) / Single State Agency Coordination: Applicants must send the PHSIS to appropriate State and local health agencies by application deadline. Comments from Single State Agency are due no later than 60 days after application deadline.

Description

The purpose of this program is to provide resource to help expand/enhance access to Medications for Opioid Use Disorder (MOUD). It is expected that this program will help to 1) increase the number of individuals with Opioid Use Disorder (OUD) receiving MOUD; and 2) decrease illicit opioid use and prescription opioid misuse.

Eligibility

Eligible applicants are domestic public and private non-profit entities.

Award Information

Funding Mechanism: Grant

Anticipated Total Available Funding: $22,575,000

Anticipated Number of Awards: Up to 30 awards (up to 22 awards for tribal applicants)

Anticipated Award Amount: Up to $750,000 per year per award

Length of Project: Up to 5 years

Cost Sharing/Match Required?: No

Proposed budgets cannot exceed $750,000 in total costs (direct and indirect) in any year of the proposed project. Annual continuation awards will depend on the availability of funds, grantee progress in meeting project goals and objectives, timely submission of required data and reports, and compliance with all terms and conditions of award.)

Contact Information

Last Updated

Last Updated: